The epidemiological picture is unambiguous. Global analyses pooling 3,663 population-representative studies covering 222 million children and adults show that obesity rates have more than doubled since 1990, and forecasts extending to 2050 project continued escalation, particularly in low- and middle-income countries that now bear the greatest economic and clinical burden. Against this backdrop, cohort studies tracking hundreds of thousands of participants for decades reveal a consistent pattern: obesity in midlife, typically defined as the forties and fifties, carries a particularly high risk of later cognitive decline and dementia. Landmark work following Kaiser Permanente members showed that central obesity in midlife nearly tripled the risk of dementia more than three decades later, and more recent mega-analyses encompassing nearly six million participants confirm that abdominal adiposity predicts cognitive impairment even after accounting for body mass index. Notably, the relationship is time-dependent, and some studies suggest that weight loss in later life does not fully erase the risk accrued during middle age, implying a window of vulnerability that may never completely reopen.

The review is careful to acknowledge complexity. In some elderly cohorts, higher body mass index in the final years of life appears protective against dementia, a finding many researchers attribute to reverse causation, as incipient neurodegenerative disease suppresses appetite and causes weight loss long before diagnosis. Sex also matters: observational data from Japanese, Chinese and Norwegian cohorts reveal divergent dementia risk patterns between men and women, likely reflecting differences in fat distribution, hormonal milieu and vascular disease. These nuances complicate simple messaging but do not undermine the central conclusion that midlife obesity is a modifiable risk factor for cognitive decline, one that the 2024 Lancet Commission on dementia prevention explicitly recognizes alongside hearing loss, depression and physical inactivity.

What makes obesity neurologically destructive? The authors trace a cascade that begins in the hypothalamus, the brain’s metabolic command center. In healthy physiology, leptin released from adipose tissue and insulin released from the pancreas signal satiety to arcuate nucleus neurons, curbing food intake. Chronic overnutrition disrupts this loop in a feed-forward spiral: elevated leptin and free fatty acids trigger inflammatory activation of hypothalamic microglia and astrocytes, which impairs leptin and insulin signaling, dulls satiety perception and permits further weight gain. Animal studies reveal that hypothalamic neurons accumulate iron, extracellular matrix remodeling becomes pathologically fibrotic, and the gliovascular interface that regulates blood flow to the hypothalamus is altered in ways that promote hypertension. Even more striking, recent work in humans and macaques demonstrates that these hypothalamic changes are not limited to rodents fed laboratory high-fat diets; they mirror the transcriptomic and structural alterations seen in obese patients undergoing neuroimaging and, in some cases, in postmortem tissue.

Beyond the hypothalamus, obesity inflicts damage on the hippocampus and prefrontal cortex, the twin pillars of memory and executive control. Neuroimaging in the UK Biobank and other large cohorts shows that higher body mass index and central adiposity are associated with reduced gray matter volume, degraded white matter integrity and lower cerebral myelin content, changes that partially mediate the link between adiposity and poorer cognitive test performance. Mechanistically, obese adipose tissue becomes inflamed and insulin resistant, releasing a chronic trickle of cytokines, free fatty acids and adipokines into the circulation. Some of these signals cross or disrupt the blood-brain barrier, activating resident microglia and provoking neuroinflammation in memory circuits. Experimental work in mice demonstrates that lipid-droplet-accumulating microglia, a dysfunctional proinflammatory state previously linked to aging, appear in the obese hippocampus, while astrocytes lose their process arborization and glutamate buffering capacity. Mitochondrial dysfunction, oxidative stress, altered microRNA expression and epigenetic changes further erode synaptic plasticity, and activation of the cGAS-STING innate immune pathway, typically associated with cellular senescence, has emerged as a shared mechanism linking metabolic stress to both obesity-related and age-related neurodegeneration.

Vascular damage compounds the neuronal injury. Obesity promotes endothelial dysfunction, cerebral small-vessel disease and blood-brain barrier leakage, all of which deprive brain tissue of adequate perfusion and permit peripheral immune cells and inflammatory mediators to infiltrate the parenchyma. Cerebrovascular dysfunction is particularly relevant because the same pathology underlies vascular dementia and worsens Alzheimer’s disease progression. Studies of middle-aged mice show that visceral adiposity alone, independent of diet-induced weight gain, is sufficient to impair cerebral blood flow regulation and cognitive performance, and human neuroimaging confirms reduced cerebral blood flow in obese adults, an effect partially reversed by physical activity. Brain insulin resistance adds another layer: neurons in the hippocampus and prefrontal cortex require insulin for synaptic plasticity, and selective insulin resistance in these regions, documented in obese humans using functional imaging, correlates with impaired memory encoding and altered food decision-making, creating a vicious cycle in which metabolic dysfunction degrades exactly the circuits needed to regulate eating behavior.

Perhaps the most consequential insight from the review is that much of this damage may be preventable or partially reversible. Weight loss interventions consistently improve cognition, with meta-analyses showing that obese and overweight individuals who lose weight exhibit gains in memory, attention and executive function. Dietary strategies ranging from the Mediterranean and MIND diets to intermittent fasting and ketogenic protocols have shown cognitive benefits in randomized trials, though effects vary in magnitude and durability. Exercise deserves particular emphasis: aerobic training restores brain insulin sensitivity in sedentary obese adults, improves executive function and working memory across age groups, enhances cerebrovascular health and, in animal models, prevents obesity-induced white matter damage even independently of weight loss. Bariatric surgery, the most effective weight-loss intervention available, produces sustained cognitive improvements measurable years after the procedure, and observational cohorts suggest reduced incidence of mild cognitive impairment and Alzheimer’s disease and related dementias among surgical patients compared with matched controls.

Pharmacotherapy is now entering the picture with unprecedented momentum. Glucagon-like peptide-1 receptor agonists, originally developed for diabetes and now widely prescribed for obesity, appear to exert neuroprotective effects beyond weight reduction. Preclinical studies show that semaglutide and exenatide dampen hypothalamic and hippocampal neuroinflammation, restore blood-brain barrier integrity and improve cognition in diabetic and obese rodent models, while clinical data from the REWIND trial and a phase 2b liraglutide study in Alzheimer’s disease hint at cognitive benefits in humans. Most notably, the large phase 3 EVOKE and EVOKE+ trials testing oral semaglutide in early-stage symptomatic Alzheimer’s disease have recently reported results, marking the first time an obesity-related metabolic therapy has been rigorously evaluated as a dementia treatment. The review also highlights emerging strategies targeting cellular senescence, hypothalamic inflammation and the gut-brain axis, including fecal microbiota changes induced by fasting that boost microglial function.

The authors close by identifying critical gaps. Most human studies are observational, leaving causality incompletely established; the optimal timing, intensity and duration of interventions remain unknown; and virtually no trials have tested whether preventing midlife obesity lowers dementia incidence decades later. Sex-specific mechanisms, the contribution of childhood adiposity to adult brain structure, and the long-term cognitive effects of GLP-1 therapies all require dedicated investigation. Yet the message for clinicians and the public is already actionable: the brain is a metabolic organ, and midlife is the decisive window. As global obesity rates continue their relentless climb, the review argues that protecting cognition in an aging world may depend less on new drugs for the dementia ward than on the unglamorous work of preventing and treating obesity decades before memory begins to fail.

Subject of Research: The effects of obesity on brain health, cognitive function and dementia risk

Article Title: Effects of obesity on brain health and cognition

Article References: McEntee, C. M., Savelieff, M. G., Noureldein, M. H., Eid, S. A., Grisold, W., Hassenstab, J. J., & Feldman, E. L. (2026). Effects of obesity on brain health and cognition. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01251-6

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01251-6

Keywords: obesity, brain health, cognition, dementia, cognitive decline, hippocampus, hypothalamus, neuroinflammation, blood-brain barrier, GLP-1 receptor agonists, bariatric surgery, midlife obesity

The numbers behind the review are stark. The latest National Health and Morbidity Survey, conducted in 2023, recorded an adult overweight and obesity prevalence of 54.4 percent, placing Malaysia second highest among Association of Southeast Asian Nations members. When the threshold is lowered to a body mass index of 23 kilograms per square metre, the cut-off increasingly considered appropriate for Asian populations, the proportion of adults at risk climbs to roughly 70 percent. Globally, obesity affected 38 percent of adults in 2020 and is projected to exceed half the world’s population by 2035, making Malaysia a case study in how rapidly middle-income nations are absorbing the metabolic consequences of nutritional transition.

The research team, led by Quan-Hziung Lim and colleagues, conducted a structured search across Web of Science, PubMed and Google Scholar, screening 3626 articles before settling on the final 179. The majority of these studies, nearly 70 percent, addressed the epidemiology of obesity, while fewer than 9 percent focused on developing new treatment modalities. Most relied on community-sampled data rather than nationally representative surveys, and the overwhelming majority were cross-sectional in design. Although randomised controlled trials increased from just three in the previous decade to 25 in the current one, most lasted less than a year, and longitudinal cohorts and pragmatic real-world trials remain scarce. This pattern, the authors note, closely mirrors the findings of an earlier scoping review covering 2008 to 2017, suggesting that the methodological profile of Malaysian obesity research has shifted only modestly over time.

One of the most consequential themes to emerge concerns how obesity itself should be measured. Malaysian studies consistently demonstrate that metabolic risk emerges well below conventional body mass index thresholds. Women with normal BMI but elevated body fat percentage, so-called normal-weight obese individuals, showed substantially higher odds of abdominal obesity, hypertriglyceridemia and hypertension. From a BMI of 23 onward, associations with undiagnosed diabetes, high blood pressure and elevated cholesterol become firmly established, and refined analyses suggest optimal hypertension prediction thresholds of around 23 kilograms per square metre for men and 24 for women. Meanwhile, waist-to-height ratio above approximately 0.5 repeatedly outperformed BMI in predicting excess adiposity and cardiometabolic disease, leading the authors to argue that a dual measurement strategy combining BMI with abdominal measures offers a pragmatic, low-cost route to earlier detection.

The review also documents a paradox familiar from international literature: in a large retrospective cohort, overweight individuals had lower all-cause mortality than those in the normal range, yet overweight and obesity contributed 7 percent of the national cancer burden, second only to tobacco smoking. Above a BMI of 30, more than three-quarters of Malaysians with obesity already carry at least one metabolic complication, and the probability of transitioning from metabolically healthy to unhealthy obesity rises by 4.4 percent with each passing year. Severe obesity at or above 35 kilograms per square metre conferred excess cardiovascular mortality for the population overall. Psychosocial evidence, though thinner, points to elevated rates of depression among people with obesity, with healthcare workers who reported depression showing double the odds of obesity, and pandemic-era surveys linking overweight status to mild-to-severe depressive symptoms.

Predisposition patterns are equally revealing. Malaysian women consistently show higher rates and risks of obesity than men, with 33 to 64 percent greater odds, and steeper increases in BMI and waist circumference with age. Prevalence peaks in middle age and declines in older adults, though the authors caution this may reflect survivorship bias rather than genuine protection. Ethnic disparities are pronounced, with Malay, Indian and other Bumiputera groups showing consistently higher odds of overweight and obesity compared with Chinese Malaysians, a pattern echoed in neighbouring Singapore. Genetic research remains exploratory, identifying variants in genes such as LEPR, ADIPOQ and FTO among local populations, but with limited immediate clinical applicability. More actionable are occupational findings: night-shift work doubled the risk of metabolic syndrome among manufacturing workers, and nurses showed particularly elevated obesity rates.

Dietary drivers form a third major thread. A quasi-historical analysis linked Malaysia’s rising obesity to a 30 percent caloric oversupply, with shifts toward wheat, sugar, meat and animal-based protein. Across multiple studies, excess intake of protein, meat, sugar, sodium and ultra-processed foods, combined with inadequate consumption of fruits, vegetables and fibre, was consistently associated with higher obesity risk. Emerging chrononutrition research suggests that meal timing matters, with late-day energy and carbohydrate intake increasing metabolic risk among people with obesity. On the policy front, the picture is sobering: four years after its introduction, nearly 80 percent of Malaysians remained unaware of the Malaysian Healthy Plate messaging concept, healthy diets remain costly, and food insecurity among rural women was paradoxically linked with higher obesity rates.

Interventional research offers cautious grounds for optimism. Twenty-two community-based lifestyle studies were reviewed, ranging from pedometer-based walking programmes to combined diet and exercise packages. The government-initiated MyBFF@home programme for urban housewives produced modest but significant reductions in weight, BMI and visceral fat at six months, though sustainability at twelve months was variable. A structured face-to-face workplace programme achieved 7 percent weight loss, substantially outperforming an online equivalent, while group-based approaches were more effective than individual counselling. Notably, 91 percent of interventions operated at the micro level, targeting individual behaviour, with almost no macro-level policy interventions tested. Modelling work suggests that meaningful weight loss through physical activity alone requires roughly 1500 MET-minutes per week, equivalent to six to seven hours of moderate activity, a bar that nearly half of sedentary Malaysians are unlikely to clear without dietary change.

Clinical treatment presents a mixed frontier. Most approved obesity medications, including newer incretin-based therapies such as semaglutide and tirzepatide, are available in Malaysia, but monthly out-of-pocket costs of 800 to 1800 ringgit are prohibitive against a median monthly income of roughly 2800 ringgit, and only about 10 percent of people with obesity are ever offered pharmacotherapy. Metabolic and bariatric surgery has expanded rapidly since 1996, with procedures more than doubling between 2010 and 2016, delivering substantial weight loss and metabolic improvement at costs between 11,000 and 30,000 ringgit. Barriers persist on both sides of the consultation: patients report weight stigma, self-blame and misperception of their own weight status, while clinicians cite time constraints and limited training. The authors conclude that Malaysia stands at a critical inflection point, requiring coordinated, whole-of-society action, stronger longitudinal and policy research, and equitable access to effective therapies to prevent the deepening of a Stage 3 obesity profile in which the burden concentrates among the poorest.

Subject of Research: Mapping and narrative review of adult overweight and obesity research in Malaysia from 2015 to 2024

Article Title: The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review

Article References: Lim, Q.-H., Khoo, J.-K., Ooi, Y.-G., Ramachandaram, A., & Ratnasingam, J. (2026). The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review. The Lancet Regional Health – Western Pacific, 74, Article 101963. https://doi.org/10.1016/j.lanwpc.2026.101963

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101963

Keywords: obesity, Malaysia, overweight, body mass index, waist-to-height ratio, public health, nutrition transition, lifestyle intervention, bariatric surgery, GLP-1 receptor agonists, National Health and Morbidity Survey, noncommunicable diseases

The commentary, authored by Syeda Bareera of Khyber Girls Medical College in Peshawar, Syed Hatim Hussain and Syed Muhammad Momin of Nowshera Medical College, Syed Muhammad Ahmad of Khyber Medical College, and Muhammad Fayyaz of Sphinghar University in Afghanistan, does not dismiss the original findings. Instead, the authors contend that the apparent link between GLP-1 receptor agonists and wound dehiscence may depend heavily on how drug exposure is defined, how rare outcomes are handled statistically, and whether wound risk is evaluated at the level of specific procedures rather than broad surgical categories. These three methodological distinctions, they argue, deserve far closer consideration before surgeons change practice or patients become alarmed. The commentary is a masterclass in the kind of critical appraisal that modern evidence-based medicine demands, particularly when a topic touches one of the most widely discussed drug classes in the world.

The first and perhaps most consequential point concerns the definition of exposure itself. The commentary authors emphasize that GLP-1 receptor agonist use should never be treated as a single, uniform perioperative exposure. There is a profound clinical difference between a patient who is actively taking a weekly injection in the days surrounding surgery, a patient who temporarily withheld the medication shortly before the operation, and a patient who discontinued therapy months earlier and has since achieved stable weight and nutritional status. Each of these scenarios carries a distinct physiological profile, and each could plausibly exert a different influence on wound healing. Yet in the studies included in the original meta-analysis, perioperative exposure timing was inconsistently reported at best. In some cohorts, cessation of the drug ranged from just one week before surgery to an average of 9.6 weeks, while in other cohorts the timing of discontinuation was not reported at all. This heterogeneity makes it genuinely difficult to know what the pooled estimates actually represent.

This ambiguity matters because clinical guidance on perioperative GLP-1 receptor agonist management has itself evolved rapidly. The initial recommendation from the American Society of Anesthesiologists advised holding weekly agents for one week before surgery, largely out of concern for residual gastric contents and aspiration risk during anesthesia. More recent multi-society guidance has shifted toward individualized assessment, weighing the timing of the last dose, the presence of gastrointestinal symptoms such as nausea and delayed gastric emptying, recent dose escalation, and patient-level risk factors. Against this moving target, the commentary authors argue that future studies must categorize exposure according to clinically meaningful perioperative windows: continued therapy, short-term withholding, prolonged withholding, or discontinuation after weight stabilization. They also suggest that investigators apply target trial emulation principles, a framework for causal inference from observational data championed by epidemiologist Miguel Hernán and colleagues, which aligns exposure assignment, follow-up, and outcome assessment with the causal question a randomized trial would ask. Only then, they contend, can observational analyses begin to disentangle the true effect of the drugs from the effects of weight change, nutrition, and timing.

The second methodological concern involves the statistical handling of rare events, a notoriously thorny problem in meta-analysis. In one of the included studies, led by Liang and colleagues, researchers reported zero surgical site infection events among GLP-1 receptor agonist users compared with seven events among controls, creating what statisticians call a single one-arm zero-event cell. Zero cells are poison for conventional risk ratio calculations, because dividing by zero is mathematically undefined and the choice of a continuity correction, a small artificial adjustment added to every cell, can materially change the pooled estimate. The original meta-analysis used Mantel-Haenszel random-effects risk ratios for binary outcomes, but the commentary authors note that it remains unclear whether a continuity correction was applied. They argue that a brief clarification of this analytic choice would help readers judge the robustness of the nonsignificant surgical site infection finding, and they cite the work of Xu and colleagues, who have proposed that meta-analysts select analytic methods according to the specific zero-event structure of their data rather than defaulting to a single approach.

Beyond clarification, the commentary authors recommend sensitivity analyses to test whether the nonsignificant infection finding survives alternative analytic conventions. These could include the Mantel-Haenszel risk difference, appropriate one-stage models, or Peto odds ratios, though the latter are only appropriate when groups are reasonably balanced and treatment effects are small. The point is not academic pedantry. When outcomes are uncommon and event counts are sparse, the apparent absence of a statistical signal can be an artifact of the analytic method rather than a genuine reflection of safety. For clinicians deciding whether to delay surgery or alter medication management, understanding the degree of uncertainty around nonsignificant findings is essential. The commentary authors argue that transparent reporting of these conventions would allow readers to interpret uncommon outcome estimates with appropriate caution, rather than mistaking statistical silence for evidence of no effect.

The third concern is arguably the most intuitive: the composite category of body contouring surgery may simply be too broad for an outcome as mechanically dependent as wound dehiscence. Panniculectomy, abdominoplasty, lipoabdominoplasty, brachioplasty, thighplasty, and mastopexy differ dramatically in incision length, flap tension, extent of undermining, dead space, drain use, and postoperative mechanical stress on the closure. High-tension abdominal procedures such as panniculectomy and abdominoplasty may involve broad dissection and challenging closure-tension dynamics, whereas mastopexy or brachioplasty involve entirely different anatomic sites, incision geometry, and postoperative forces. These factors are directly related to dehiscence risk and are not interchangeable across procedure types. Pooling them into a single body contouring category risks diluting or distorting any true procedure-specific signal, and the commentary authors argue that future work should stratify analyses by procedure type wherever sample size permits, particularly separating high-tension abdominal operations from other contouring procedures.

The commentary extends this procedural critique to the outcome definitions themselves. Surgical site occurrences, as commonly reported in the plastic surgery literature, combine events with fundamentally different mechanisms: infection, seroma, hematoma, and dehiscence. The Centers for Disease Control and Prevention’s National Healthcare Safety Network framework links surgical site infection surveillance to operative procedure category and tissue depth, while leading plastic surgery researchers such as Gabriel, Gupta, and Orgill have emphasized the clinical importance of distinguishing among these wound events rather than treating them as interchangeable. A pooled estimate that blends a seroma with a wound separation tells clinicians very little about either. The commentary authors call for predefined wound-event definitions, standardized follow-up intervals, and procedure-stratified analyses in future research, arguing that only this level of granularity will reveal which patients, which operations, and which perioperative management strategies genuinely warrant additional caution.

Crucially, the authors are careful to frame their critique as a call for cautious interpretation rather than a rejection of the original work. They acknowledge that the finding of a possible association between GLP-1 receptor agonist use and wound dehiscence is clinically important, particularly as plastic surgeons increasingly encounter patients arriving after pharmacologic weight loss, often with altered nutritional status, rapid changes in tissue quality, and complex medication histories. The current evidence, they write, is clinically valuable but limited by heterogeneity and variable reporting across the underlying primary studies. Their goal is to ensure that the dehiscence signal stimulates better-designed research rather than premature clinical dogma. In an era when a single headline about a blockbuster drug class can reshape patient behavior overnight, the distinction between a preliminary association and an established risk is not a technicality; it is the difference between informed decision-making and unnecessary alarm.

The broader lesson of this scholarly exchange extends well beyond GLP-1 receptor agonists and the operating room. It illustrates how the quality of a meta-analysis is ultimately bounded by the quality and granularity of the primary studies it pools, and how seemingly technical choices, the definition of an exposure window, the treatment of a zero cell, the boundaries of a surgical category, can shape conclusions that reach millions of patients. As the obesity medication revolution continues and the wave of post-weight-loss body contouring surgery swells, the surgical community now has both a warning and a roadmap: take the wound-healing question seriously, but answer it with the methodological rigor it demands. Patients contemplating surgery while on these medications should discuss timing and individual risk with their surgical and prescribing teams, guided by evolving multi-society recommendations rather than by any single pooled estimate.

Subject of Research: Perioperative safety of GLP-1 receptor agonists in body contouring surgery

Article Title: Comment on: Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis

Article References: Bareera, S., Hussain, S. H., Momin, S. M., Ahmad, S. M., & Fayyaz, M. (2026). Comment on: Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis. BMC Plastic and Reconstructive Surgery, 2(1), Article 20. https://doi.org/10.1186/s44452-026-00033-9

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00033-9

Keywords: GLP-1 receptor agonists, body contouring surgery, wound dehiscence, meta-analysis, systematic review, surgical site infection, perioperative management, plastic surgery, weight loss medications, zero-event studies, surgical complications, target trial emulation

The letter is a critical appraisal of a real-world study by Ahn and colleagues that examined whether GLP-1RAs act as cardiovascular risk modifiers in people with obstructive sleep apnea and obesity. Real-world studies of this kind have become enormously influential because they mine large clinical databases to answer questions that randomized trials either have not yet addressed or cannot practically address. With millions of patients now prescribed GLP-1RAs for type 2 diabetes, obesity, and increasingly for their demonstrated cardiovascular benefits, the stakes for getting these observational analyses right could hardly be higher. Policy decisions, prescribing patterns, and reimbursement frameworks increasingly rest on the kind of database evidence that Sarıoğlu’s letter scrutinizes.

At the heart of the critique lies a technical concept that has shaped pharmaco-epidemiology for nearly two decades. Immortal time bias arises when a period of time during which the outcome of interest cannot occur is improperly included in one group’s follow-up, typically the treated group. The classic formulation comes from epidemiologist Samy Suissa, whose 2008 paper in the American Journal of Epidemiology laid out how this bias operates: if researchers define the exposed group by a prescription that occurs sometime after cohort entry, but count that patient’s follow-up from the moment of entry, the patient must survive long enough to receive the prescription. That guaranteed survival window, the ‘immortal time,’ makes the treated group appear artificially protected, generating spuriously favorable results for the drug.

Sarıoğlu points out that this structure is particularly easy to fall into when studying GLP-1RAs, because these drugs are often initiated months or even years after a patient first enters the health system with obesity, sleep apnea, or diabetes. When investigators anchor their analysis at the date of an obstructive sleep apnea diagnosis or at a baseline clinic visit, but classify patients as GLP-1RA users only once a prescription appears later in their record, the exposed group has, by construction, accumulated event-free time before treatment ever began. Unless the analysis explicitly accounts for that window—through techniques such as time-dependent exposure modeling, matching on the time to treatment, or active-comparator new-user designs—the resulting hazard ratios can suggest cardiovascular protection that reflects study design rather than pharmacology.

The letter also situates its argument within a broader and ongoing refinement of how epidemiologists understand these biases. A 2025 paper by Miguel Hernán and colleagues in the journal Epidemiology provided a structural description of the family of biases that generate immortal time, framing them through the lens of causal diagrams and target trial emulation. That work emphasized that immortal time bias is not a single mistake but a constellation of design choices—how cohorts are defined, how exposure is classified, how follow-up begins and ends—that collectively manufacture a comparison between people who could not yet have experienced an event and those who could. Sarıoğlu’s letter applies this modern framework to the specific case of GLP-1RAs in sleep apnea populations, effectively asking whether the original study emulated the randomized trial it intended to mimic.

The target trial framework, as it is known, asks investigators to specify, before touching the data, the randomized trial they would ideally conduct: who would be eligible, how treatment would be assigned, when follow-up would start, and what outcome would be measured. In a well-executed emulation, the moment of cohort entry and the moment treatment is assigned coincide, or the analysis explicitly handles the gap between them. When they diverge—as they do whenever a prescription recorded at an arbitrary later date defines the exposed group—the emulation drifts away from the trial it was meant to mirror, and the divergence is precisely where bias enters. Sarıoğlu’s central claim is that the timing of exposure classification in real-world cardiovascular analyses of GLP-1RAs represents exactly such a divergence, and that readers should interpret effect estimates from such studies with corresponding caution.

Why does this matter so much for this particular drug class and this particular patient population? Obstructive sleep apnea affects roughly a billion people worldwide and is strongly associated with obesity, hypertension, arrhythmias, and increased cardiovascular mortality. GLP-1RAs have generated intense excitement because randomized trials in other populations, notably patients with type 2 diabetes and established cardiovascular disease, showed meaningful reductions in major adverse cardiovascular events. Translating those findings to sleep apnea populations through observational data is an attractive and legitimate research strategy. But it is also a strategy in which the exposure is highly patterned by the very health trajectories under study: patients who remain well enough, engaged enough with care, and clinically stable enough to receive a GLP-1RA prescription are systematically different from those who deteriorate, drop out, or die before such a prescription is written. Any analysis that does not neutralize this selection can convert healthier-patient dynamics into apparent drug benefit.

The letter does not claim that GLP-1RAs lack cardiovascular benefits, nor does it assert that the original study’s conclusions are necessarily wrong. Its point is narrower and, in a sense, more important: the direction and magnitude of any bias introduced by exposure timing cannot be determined from the published results alone, and the credibility of real-world evidence for this drug class depends on design features that must be transparently reported. Sarıoğlu, writing as the sole author of the letter, conceived the commentary, reviewed the relevant literature, and drafted and revised the manuscript, drawing on no external funding and declaring no competing interests. The letter is based exclusively on critical appraisal of previously published work and involves no new data collection, which means its contribution is methodological rather than empirical—it is a lens, not a dataset.

The wider lesson extends well beyond sleep medicine. As GLP-1RAs are studied for an ever-expanding list of outcomes—from kidney disease and heart failure to dementia and addiction—real-world database studies will continue to proliferate, and each carries the same vulnerability if exposure timing is mishandled. The epidemiological community has developed reliable remedies: defining cohort entry at the moment of treatment eligibility, modeling exposure as a time-varying covariate, using new-user designs that exclude prevalent users, and emulating target trials with explicit cloning, censoring, and weighting strategies. Sarıoğlu’s letter serves as a reminder that applying these tools is not pedantic hair-splitting but the difference between evidence that can guide patient care and evidence that merely reflects who managed to stay alive and in care long enough to fill a prescription.

Published on 9 September 2026 as a letter to the editor in the Journal of Clinical Sleep Medicine, the commentary adds a careful methodological voice to one of the most consequential drug-evidence debates of the decade. Whether future real-world analyses of GLP-1RAs in obstructive sleep apnea and obesity will confirm, revise, or overturn the cardiovascular signals reported to date remains an open question. What the letter makes clear is that answering it responsibly requires paying close attention not just to whether patients took these drugs, but to precisely when the clock on their follow-up started—and whether that clock was fair to both the treated and the untreated.

Subject of Research: Methodological bias in real-world observational studies of GLP-1 receptor agonist exposure timing and cardiovascular risk in obstructive sleep apnea and obesity

Article Title: Timing of GLP-1RA exposure in real-world cardiovascular risk analyses

Article References: Sarıoğlu, G. (2026). Timing of GLP-1RA exposure in real-world cardiovascular risk analyses. Journal of Clinical Sleep Medicine, 22(1), Article 161. https://doi.org/10.1007/s44470-026-00188-3

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00188-3

Keywords: GLP-1 receptor agonists, immortal time bias, cardiovascular risk, obstructive sleep apnea, obesity, pharmaco-epidemiology, real-world evidence, observational studies, target trial emulation, type 2 diabetes, methodology, Journal of Clinical Sleep Medicine

The study, led by Chia Siang Kow and colleagues, took a fresh statistical look at the six clinical studies and ten intervention arms that tracked semaglutide or tirzepatide after treatment discontinuation, drawing on data covering 1776 participants. Rather than relying on simple pooled averages, the researchers reconstructed the arm-level data and applied a Bayesian hierarchical longitudinal model, a statistical framework that jointly models repeated measurements over time while explicitly accounting for variability between study arms. This approach allowed the team to go beyond asking how many kilograms are regained each month and instead translate the trajectory into clinically meaningful milestones, complete with full probability distributions that quantify uncertainty.

The headline finding is that people who stop taking these medications regain an estimated 1.04 kilograms per month on average, with a 95 percent credible interval of 0.80 to 1.29 kilograms per month. The modelled average participant had lost 15.35 kilograms by the time treatment ended. Under the linear model assumed by the researchers, half of that hard-won loss was projected to return within about 7.5 months, and participants were projected to be back at their baseline weight by roughly 15 months after stopping. In practical terms, the clock on the treatment’s benefits starts ticking almost the moment the final injection wears off.

The month-by-month trajectory is particularly striking. Within the follow-up window actually observed in the trials, which extended to 52 weeks, the modelled average weight change was still below baseline at six months, at minus 9.12 kilograms, but by then approximately 41 percent of the initial weight loss had already been regained. At nine months the average was minus 6.01 kilograms, corresponding to 62 percent regained, and by twelve months the average stood at minus 2.90 kilograms, meaning roughly 83 percent of the lost weight had returned. The posterior probability that the average trajectory had regained at least half of the initial weight loss climbed from just 12.5 percent at six months to 86.7 percent at nine months and a near-certain 99.5 percent at one year.

It is important to understand the mathematical machinery behind these numbers. The researchers assumed a constant linear regain slope rather than a curving trajectory, a choice justified because follow-up data were sparse and a prior systematic review had found that adding a nonlinear term did not improve model fit. Each study arm was treated as a repeated-measures trajectory with its own random effects for both the weight loss present at discontinuation and the subsequent regain rate. The Bayesian estimation relied on full Markov chain Monte Carlo sampling, with convergence confirmed by R-hat statistics hovering at approximately 1.00 and large effective sample sizes for the key slope parameters. Estimates extending beyond the maximum observed follow-up of 52 weeks, including the projected return to baseline at 15 months, are explicitly flagged as extrapolations of the average trajectory rather than directly observed outcomes.

One of the most provocative aspects of the analysis is its comparison of the two drugs. Tirzepatide arms showed a numerically faster unadjusted regain rate of 1.10 kilograms per month compared with 0.89 kilograms per month for semaglutide, and projected return to baseline was correspondingly sooner, at roughly 14.5 months versus 17.3 months. But when the researchers adjusted for the magnitude of initial weight loss and post-discontinuation support in a Bayesian meta-regression, the drug difference essentially vanished. The adjusted effect of tirzepatide versus semaglutide was a negligible minus 0.04 kilograms per month, with a posterior probability of only 40.2 percent that tirzepatide regains faster. In other words, the apparent difference in rebound between the two drugs likely reflects differences in how much weight was lost in the first place, not any inherent difference in the physiology of regain.

That observation points to one of the study’s most interesting exploratory findings: greater initial weight loss was itself the strongest directional predictor of faster absolute regain. Each additional 5 kilograms of weight lost during treatment was associated with a 0.20 kilograms per month faster regain slope, a result carrying a 92.1 percent posterior probability, though the credible interval included zero. The authors caution that this association may partly reflect mathematical coupling, since a larger initial loss simply creates more opportunity for absolute regain. Meanwhile, behavioural or lifestyle support after discontinuation showed a directional association with slower regain, an estimated effect of minus 0.19 kilograms per month with an 87.2 percent probability of benefit, but the imprecise estimate means the finding remains inconclusive. With only ten intervention arms available, all meta-regression results are explicitly exploratory and hypothesis-generating rather than definitive.

Sensitivity analyses reinforced the robustness of the core conclusion. A contrast analysis using the randomised differences between intervention and control arms showed a similar direction of effect, though with less precision. A post hoc analysis excluded the three SURPASS-1 arms, which came from a trial of adults with Type 2 diabetes receiving tirzepatide as glucose-lowering monotherapy rather than for weight management. Excluding those arms left the monthly regain slope essentially unchanged at 0.95 kilograms per month, though the projected time to 50 percent regain lengthened to 9.42 months because the average initial weight loss among the remaining arms was greater. The qualitative message of rapid regain survived every stress test the researchers applied.

The clinical implications are considerable. Because discontinuation is common in routine practice, driven by cost, tolerability problems, access restrictions, treatment fatigue and genuine uncertainty about how long therapy should last, the findings suggest that clinicians should plan proactive monitoring within the first several months after stopping treatment, when early regain can be identified and maintenance strategies reassessed. The authors are careful to note that their data do not determine whether dose tapering, lower-dose maintenance, drug switching, intermittent treatment or any specific behavioural programme can prevent regain; those questions require dedicated trials. They also stress that the analysis captured body-weight trajectories only, so any statements about cardiometabolic benefits, cost-effectiveness or the consequences of fixed-duration treatment policies remain hypotheses informed by the weight pattern rather than direct findings.

What the study ultimately delivers is a statistically rigorous quantification of something patients and clinicians have long suspected: incretin-based anti-obesity medications suppress appetite and enable weight loss while they are active, and withdrawing that physiological support removes the very mechanism holding the weight down. Between-study heterogeneity was real but moderate, with a between-arm standard deviation of 6.78 kilograms for initial weight loss and 0.26 kilograms per month for the regain slope, suggesting that while individual experiences vary, the average trajectory is consistently steep. As these drugs reshape obesity medicine and public expectations, the analysis argues that their long-term value must be judged not only by the dramatic losses achieved during treatment but by an honest accounting of what follows when the treatment ends, and by research that extends follow-up beyond one year, reports regain in both absolute and percentage terms, and directly tests the maintenance strategies that patients will increasingly demand.

Subject of Research: Weight regain after discontinuation of the incretin-based anti-obesity medications semaglutide and tirzepatide

Article Title: Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Article References: Kow, C. S., Thiruchelvam, K., Ramachandram, D. S., & Zaihan, A. F. (2026). Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5), Article e70325. https://doi.org/10.1002/edm2.70325

Image Credits: AI Generated

DOI: 10.1002/edm2.70325

Keywords: semaglutide, tirzepatide, weight regain, obesity, incretin therapies, GLP-1 receptor agonists, Bayesian meta-analysis, treatment discontinuation, weight loss maintenance, anti-obesity pharmacotherapy, Weight, Regain

The research team searched five major databases—PubMed, Embase, Scopus, Web of Science and the Cochrane Central Register—through November 2025, screening more than 2,400 records under PRISMA 2020 guidelines. From that effort, eight unique studies contributing ten distinct comparisons made the final synthesis. Five comparisons came from propensity score-matched observational cohorts, four from nonmatched cohorts, and one from randomized trial data, including prespecified analyses of the FLOW and SOUL trials. The researchers deliberately excluded studies that reported only composite major adverse cardiovascular events, or MACE, insisting instead on separate data for myocardial infarction and stroke—a decision that proved scientifically decisive.

That insistence matters because composite endpoints have long been a blind spot in cardiovascular outcomes research. Myocardial infarction is fundamentally a coronary atherothrombotic event, driven by plaque rupture and clot formation in the heart’s arteries, while stroke is a heterogeneous condition involving both cerebrovascular atherosclerosis and cardioembolic pathways. Pooling these biologically distinct events into a single MACE score can mask divergent treatment effects, much like averaging the temperatures of two different cities. By disaggregating the endpoints, the researchers could ask a sharper question: does dual therapy protect the coronary arteries and the cerebral circulation equally?

The answer, intriguingly, is no. For myocardial infarction, combination therapy was associated with a pooled hazard ratio of 0.79, meaning a 21 percent relative risk reduction compared with monotherapy overall. Yet when the investigators stratified by comparator, a telling pattern emerged: dual therapy significantly outperformed SGLT2 inhibitor monotherapy for MI prevention (hazard ratio 0.74), but showed no statistically significant advantage over GLP-1 receptor agonist monotherapy (hazard ratio 0.80, confidence interval 0.55 to 1.16). In other words, the coronary benefit appears to be carried almost entirely by the GLP-1 receptor agonist component of the combination.

This finding aligns closely with the biology established by landmark cardiovascular outcome trials. GLP-1 receptor agonists exert robust antiatherosclerotic and antiinflammatory effects—improving endothelial function, plaque stability, body weight and blood pressure—making them particularly well suited to preventing atherothrombotic coronary events. In the HARMONY Outcomes trial, for instance, the GLP-1 agonist albiglutide reduced MACE, and among the individual components only myocardial infarction showed a statistically significant reduction. SGLT2 inhibitors, by contrast, deliver their most profound and reproducible benefits in heart failure and kidney protection, with more modest effects on atherosclerotic events. Adding an SGLT2 inhibitor to a patient already on a GLP-1 agonist may therefore offer limited incremental defense against coronary ischemia, because the atherothrombotic pathways are already being substantially modulated.

Stroke told a different and arguably more exciting story. Combination therapy was associated with a 15 percent lower stroke risk overall (hazard ratio 0.85), and unlike the MI findings, this benefit outperformed both individual drug classes: a 27 percent reduction versus SGLT2 inhibitor monotherapy and a statistically significant 8 percent reduction versus GLP-1 receptor agonist monotherapy. The advantage was concentrated in ischemic stroke specifically, with a hazard ratio of 0.67. The researchers propose a dual-pathway synergy: while the GLP-1 agonist stabilizes the cerebrovascular wall against atherosclerosis, the SGLT2 inhibitor contributes hemodynamic offloading, blood pressure lowering and possible antiarrhythmic effects. Supporting this framework, prior mechanistic studies have shown that combining the two agents improves endothelial glycocalyx integrity, pulse wave velocity, central systolic blood pressure and left atrial strain—parameters directly relevant to cardioembolic stroke risk.

Perhaps the most clinically provocative result was the age interaction. The cerebrovascular benefit appeared dramatically stronger in adults aged 65 and older, who showed a remarkable 50 percent relative reduction in stroke risk (hazard ratio 0.50), an effect absent in younger cohorts. The authors note that older adults carry a higher baseline burden of arterial stiffness, chronic kidney disease and occult atrial arrhythmias—pathophysiological domains where combined vascular and cardiorenal risk reduction may yield the greatest absolute benefit. However, they caution that this age-related signal, though statistically significant, rests on a limited number of comparisons and could reflect chance.

The analysis was not without warning signs. Substantial heterogeneity characterized both endpoints, with I-squared values of 72.8 percent for MI and 63.5 percent for stroke. Sensitivity analyses revealed that nonmatched observational cohorts produced a larger MI association (hazard ratio 0.67) than propensity-matched comparisons (hazard ratio 0.87), a statistically significant difference that suggests residual confounding and treatment-selection bias may inflate the apparent benefit in less rigorous study designs. One exploratory subgroup even showed elevated stroke risk among baseline insulin users (hazard ratio 2.33), though this rested on a single comparison and may simply reflect confounding by indication, since insulin use often marks more advanced disease. Applying the GRADE framework, the researchers rated the overall certainty of evidence as very low for both endpoints.

The authors are emphatic that these findings are hypothesis-generating rather than practice-changing. Current American Diabetes Association guidelines already recommend tailoring therapy to individual cardiovascular risk profiles, and both drug classes are well established individually; the new analysis does not mandate dual therapy solely for MI or stroke prevention. Instead, the results suggest that when both agents are already clinically appropriate for a patient’s broader cardiometabolic needs—glycemic control, weight management, heart failure risk—the potential for vascular-specific protection adds a further rationale. Notably, the safety profile of the combination appears favorable, with adverse events remaining largely class-specific: genital mycotic infections and rare euglycemic ketoacidosis for SGLT2 inhibitors, gastrointestinal intolerance for GLP-1 agonists, and a need for careful insulin adjustment to avoid hypoglycemia.

What the field needs next, the researchers argue, are dedicated prospectively powered randomized trials designed from the outset to compare combination therapy against active monotherapy, powered for individual coronary and cerebrovascular events rather than composite MACE. Such trials should capture stroke subtypes, fatal versus nonfatal events, and the sequencing question of simultaneous initiation versus sequential add-on. Until then, this meta-analysis offers a compelling physiological preview: two blockbuster drug classes, each famous in its own right, may protect the heart and the brain through complementary, nonredundant mechanisms—and the patients who stand to gain the most from putting them together may be older adults at high cerebrovascular risk.

Subject of Research: The effect of combined SGLT2 inhibitor and GLP-1 receptor agonist therapy on myocardial infarction and stroke risk in adults with type 2 diabetes

Article Title: Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Article References: Ghafoury, R., Naghshbandi, M., Malek, M., Kalra, S., Ismail-Beigi, F., & Khamseh, M. E. (2026). Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01911-2

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01911-2

Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, myocardial infarction, stroke, combination therapy, meta-analysis, cardiovascular outcomes, Diabetes Therapy, ischemic stroke, cardiometabolic medicine, GRADE certainty

The scale of the blind spot is considerable. Population studies and meta-analyses cited by the group show that MASLD increases the risk of fatal and non-fatal cardiovascular events, new-onset heart failure, and atrial fibrillation. One recent meta-analysis of around 11 million individuals linked fatty liver disease to a significantly elevated risk of incident heart failure, and biopsy-proven cohorts have revealed that incident heart failure is both common and frequently missed in these patients. The group describes a global cardiovascular–liver–metabolic ‘syndemic’, in which shared risk factors such as obesity, type 2 diabetes and dyslipidaemia drive parallel epidemics of liver fibrosis and cardiovascular disease. When each speciality manages only its own organ, patients fall through the gaps, interventions arrive late, and outcomes suffer on both fronts.

At the mechanistic level, the liver and the heart are locked in bidirectional dialogue. The steatotic liver acts as an endocrine and inflammatory organ, exporting excess very-low-density lipoproteins, pro-inflammatory cytokines and other mediators that promote endothelial dysfunction, atherosclerosis and myocardial remodelling. Hepatic insulin resistance aggravates systemic metabolic dysfunction, while emerging proteomic work suggests that distinct organ-damage signatures can flag MASLD patients at risk of systemic complications before overt disease develops. Conversely, cardiac dysfunction feeds back on the liver: elevated central venous pressure in heart failure congests the hepatic circulation, and experimental evidence shows that myocardial infarction can accelerate steatohepatitis by triggering immunoinflammatory responses. Recent research also suggests that low-to-moderate alcohol intake and hypertension both amplify fibrosis progression in MASLD, tightening the links between metabolic, hepatic and cardiac trajectories.

A central tenet of the recommendation is that liver fibrosis, rather than simple steatosis, is the pivotal risk stratifier. Fat in the liver alone carries a more modest prognostic signal; the accumulation of fibrous scar tissue is what tracks with hepatic decompensation, cardiovascular events and mortality. The authors therefore propose that the degree of fibrosis should guide not only hepatological monitoring but also cardiovascular risk assessment, effectively serving as a shared currency between the two disciplines. Data from the global burden of disease project and longitudinal cohort analyses indicate that fibrosis stage predicts clinical events across the MASLD spectrum, including in so-called lean individuals, and that patients with coexisting cardiovascular–kidney–metabolic syndrome progress to advanced fibrosis and liver-related events more rapidly.

To operationalise this insight, the paper lays out a stepwise screening algorithm designed for real-world efficiency. First-line assessment uses the fibrosis-4 index, a simple calculation from age, aminotransferases, platelet count and aspartate aminotransferase that can be computed in any clinic. Patients flagged by this inexpensive test proceed to vibration-controlled transient elastography, a non-invasive ultrasound-based measurement of liver stiffness, and those with concerning results are referred for specialist evaluation. This cascade, the authors argue, enables identification of clinically significant fibrosis and high-risk metabolic phenotypes without resorting to liver biopsy in most patients, and it aligns with recent European screening studies that found previously unrecognised liver fibrosis to be common in the general population. The same non-invasive tools can be deployed longitudinally, since changes in stiffness and fibrosis markers over time carry prognostic information for both organ systems.

On the therapeutic front, the framework recommends pairing intensive lifestyle intervention with cardiometabolic drug classes that deliver dual liver and cardiovascular benefits. Glucagon-like peptide 1 receptor agonists have now demonstrated histological improvement in steatohepatitis in phase 3 trials of semaglutide and tirzepatide, alongside established reductions in major adverse cardiovascular events, heart failure hospitalisation and, for tirzepatide, benefit in obesity-related heart failure with preserved ejection fraction. Sodium–glucose cotransporter 2 inhibitors similarly combine cardiovascular and renal protection with emerging evidence of reduced liver-related events and mortality in patients with MASH cirrhosis. Meanwhile, resmetirom, the first approved liver-directed therapy for MASH with moderate to advanced fibrosis, addresses the hepatic side of the equation and has gained regulatory approval in both the United States and Europe. Statins, the authors add, remain underused in MASLD despite evidence of multisystem benefit and reassuring hepatic safety.

The recommendation does not stop at individual drugs; it embeds them within a structured metabolic care framework that treats the patient as a cardiometabolic whole. Data-driven cluster analyses and polygenic risk scores now identify biologically distinct MASLD subtypes, some predisposed to severe fibrosis and others to cardiometabolic complications, offering a route to precision-matched therapy. The authors argue that cardiovascular risk calculators such as SCORE2 and the American Heart Association’s PREVENT equations should be complemented by markers that capture the MASLD-specific burden, including high-sensitivity C-reactive protein, lipoprotein(a), inflammation indices and non-invasive fibrosis measures. They also stress aggressive management of hypertension, diabetes and dyslipidaemia, careful attention to alcohol consumption, and recognition that cardiovascular events themselves accelerate liver disease progression.

Implementation, the group acknowledges, is the hardest part. Quality-standards audits in the United Kingdom have documented wide variation in fatty liver disease care delivery, and therapeutic inertia remains endemic in cardiovascular prevention. The paper therefore proposes concrete pathways: bidirectional referral arrangements in which cardiologists screen for MASLD using FIB-4 and hepatologists routinely assess cardiovascular risk; shared care clinics and multidisciplinary teams; embedded non-invasive liver measures in both cardiology and hepatology workflows; and co-management protocols that specify who monitors what, and when. Clinical trials, they contend, should likewise embed dual hepatic and cardiovascular endpoints, a roadmap recently elaborated for multiorgan trial design spanning the MASLD–MASH–cardiovascular–kidney–metabolic spectrum. Without such integration, the benefits of newly available therapies risk accruing to the minority of patients who already navigate both specialities successfully.

The paper’s broader message is a reframing of MASLD itself: from an incidental imaging finding, or a condition waiting for cirrhosis, to a systemic metabolic disease whose most lethal complication is often cardiac. With global projections suggesting the MASLD burden will continue to climb through 2050, and cause-specific mortality data showing cardiovascular death outpacing liver-related death in these patients, the stakes of getting co-management right are high. The authors, whose work is supported by the CHAIN Consortium, position their expert recommendation as a practical bridge between cardiology and hepatology, one built on existing tools rather than speculative technology. If adopted, the framework could convert a fragmented two-organ problem into a single, coherent cardiometabolic care pathway, closing screening gaps, sequencing therapies by fibrosis stage and cardiovascular risk, and ultimately reducing the twin burdens of heart disease and liver failure in one of the world’s most common chronic conditions.

The shift in terminology itself reflects the evolving understanding of the disease. The multisociety Delphi consensus that introduced the MASLD nomenclature in 2023 deliberately replaced older terms to emphasise metabolic dysfunction as the unifying mechanism, and to allow coexistence with other hepatic conditions such as alcohol-associated liver disease. This reframing matters clinically, because the metabolic cluster that defines MASLD overlaps almost completely with the risk factors tracked by cardiovascular prevention guidelines, making the liver a natural target organ for cardiometabolic screening programmes.

Epidemiological data underpinning the recommendation are substantial. The Global Burden of Disease Study 2023 analysis projected continued growth in MASLD prevalence through mid-century, and systematic reviews have documented that hepatic and extrahepatic cancers, cardiovascular events and chronic kidney disease collectively account for a large share of adverse outcomes, with liver-related mortality no longer dominating the natural history except in advanced fibrosis. This changing pattern of mortality is precisely why the authors argue that risk stratification must serve two organ systems simultaneously.

The screening tools proposed also carry caveats worth noting. The fibrosis-4 index performs well at ruling out advanced fibrosis but has limited specificity, particularly in middle-aged patients with obesity or diabetes, where false positives are common and can drive unnecessary referrals. Vibration-controlled transient elastography offers better discrimination but can be unreliable in obesity and in acute hepatic inflammation, and access remains uneven across health systems. The stepwise algorithm therefore functions best as a triage instrument, reserving liver biopsy for indeterminate cases where the result would change management.

On the pharmacological side, the dual-benefit argument is supported by an expanding evidence base. Incretin-based therapies act on hepatic, adipose and central nervous system pathways that influence appetite, insulin sensitivity and hepatic fat flux, while sodium–glucose cotransporter 2 inhibitors shift myocardial metabolism and reduce cardiac congestion. Resmetirom, a selective thyroid hormone receptor-beta agonist, targets hepatic mitochondrial function and fat oxidation, complementing rather than replacing systemic metabolic therapy. The authors emphasise that sequencing these agents according to fibrosis stage and cardiovascular risk profile remains an open question that only trials with dual endpoints can resolve, reinforcing their call for co-management pathways embedded in routine practice.

Subject of Research: Heart–liver co-management and multidisciplinary cardiometabolic care in metabolic dysfunction-associated steatotic liver disease (MASLD)

Article Title: Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework

Article References: Zhou, X.-D., Jeong, S., Chen, Q.-F., Targher, G., Byrne, C. D., Chew, N. W. S., Younossi, Z. M., Lip, G. Y. H., Tilg, H., George, J., Stefan, N., Sperling, L. S., Luu, H. N., Fudim, M., Loomba, R., & Zheng, M.-H. (2026). Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01255-z

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01255-z

Keywords: MASLD, cardiovascular disease, liver fibrosis, heart–liver co-management, FIB-4, transient elastography, GLP-1 receptor agonists, SGLT2 inhibitors, resmetirom, cardiometabolic syndrome, risk stratification, multidisciplinary care

The rationale for repurposing antidiabetic drugs against dementia rests on a concept researchers have provocatively dubbed “type 3 diabetes.” Older adults with type 2 diabetes (T2D) face roughly a twofold increased risk of cognitive impairment compared with people without the disease, and patients with T2D develop Alzheimer’s disease (AD) at higher rates than the general population. At the center of this link sits brain insulin resistance. When neurons stop responding properly to insulin, the consequences cascade through exactly the pathways that define AD pathology: increased production and accumulation of beta-amyloid (Aβ), formation of neurofibrillary tangles through hyperphosphorylation of tau protein, oxidative stress, and escalating neuroinflammation. Studies of brain tissue from patients with AD have even demonstrated inactivation of the insulin-like growth factor 1 receptor and insulin receptor substrates 1 and 2—molecular signatures strikingly similar to the peripheral insulin resistance seen in diabetic patients.

The mechanistic detail is intricate. Chronic hyperglycemia and hyperinsulinemia promote oxidative stress, endothelial damage, and the formation of advanced glycation end products (AGEs) that impair neuronal function, while insulin resistance increases blood–brain barrier permeability, allowing peripheral inflammatory signals to flood the brain, where reactive astrocytes and activated microglia amplify the damage in a self-perpetuating cycle. Disrupted insulin signaling also derails mitochondrial structure and function, choking off the energy metabolism neurons need, and impairs the synthesis and release of neurotransmitters and neurotrophic factors in memory-critical regions. Cross-sectional imaging studies point to structural correlates as well: reductions in gray matter volume and pronounced hippocampal and amygdalar atrophy may account for the memory impairment so often observed in patients with T2DM. Elevated serum levels of inflammatory markers such as interleukin-6 and high-sensitivity C-reactive protein have been linked to increased risk of mild cognitive impairment (MCI), further tightening the association between metabolic dysfunction and eroding cognition.

Against this backdrop, GLP-1 receptor agonists have emerged as the most intensively studied candidates. GLP-1 receptors are expressed in brain regions central to memory and cognition, including the hippocampus—the same territory compromised earliest in AD pathogenesis. Crucially, these drugs can cross the blood–brain barrier. Once inside, they appear to act through multiple converging mechanisms: they re-sensitize insulin signaling by raising PI3K levels, which rescues the pathway and inhibits GSK3β activity; they suppress Aβ-induced excitotoxicity; they reduce Aβ production by inhibiting BACE1 while boosting α-secretase; and they elevate brain-derived neurotrophic factor (BDNF), a molecule that promotes neuronal survival, neurogenesis, synaptic plasticity, and remyelination. Because GLP-1 receptors are also expressed on glial cells, the drugs can dampen neuroinflammation directly by activating the PI3K/Akt pathway and inhibiting NF-κB, thereby lowering pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6 and restraining microglial and astrocyte activation.

Preclinical data have been striking, if not universally consistent. In diabetic rats and 5xFAD mouse models of AD, liraglutide treatment reduced amyloid-β plaque deposition, tamed astrocyte reactivity and microglial activation in the cortex and hippocampus, and prevented synaptic loss. Semaglutide, in animal models, appears to shift microglia from the pro-inflammatory M1 state toward the neuroprotective M2 phenotype, a polarization change correlated with rescued cognition and reduced neuroinflammatory markers such as Iba-1 and glial fibrillary acidic protein. Lixisenatide, an exenatide analogue, prevented Aβ-related synaptic plasticity and spatial memory impairment by blocking Aβ-induced hippocampal GSK3β activation, and decreased both amyloid plaques and neurofibrillary tangles while enhancing long-term potentiation. The review’s authors are careful to note, however, that not all animal studies concur—some models failed to show reduced Aβ accumulation or cognitive gains, differences likely attributable to genetic background, dosing regimens, treatment duration, and the stage of disease at which treatment began.

SGLT2 inhibitors, best known for their renal and cardiovascular benefits, are building their own neuroprotective case. These lipid-soluble drugs cross the blood–brain barrier and engage SGLT1 and SGLT2 co-receptors expressed in the human central nervous system, including the hippocampus, where they help maintain glucose homeostasis and support learning. In db/db mice, SGLT2i treatment improved learning and memory by reducing brain inflammation and oxidative stress while ameliorating neuronal plasticity and mitochondrial dysfunction. Empagliflozin and dapagliflozin increase neurotrophic factors such as BDNF, GDNF, and VEGF, enhance synaptophysin expression, and restore the PI3K/Akt/GSK-3β pathway. In AD animal models, SGLT2is reduce tau phosphorylation and senile plaque density, and they appear to protect neurons from apoptosis by reducing Bax and caspase-3 expression while raising Bcl-2 levels. DPP4 inhibitors add a further layer: linagliptin attenuated Aβ-induced cytotoxicity in human neuronal cells by restoring insulin signaling through increased IRS-1 and Akt phosphorylation, while a novel DPP4 inhibitor, gramcyclin A, produced dose-dependent improvements in spatial learning in triple transgenic mice alongside reduced Aβ and p-tau levels and enhanced brain glucose uptake.

The clinical picture is genuinely mixed—and the review does not shy away from that. Early signals were tantalizing: a phase IIb ELAD study of liraglutide in 204 patients with mild AD dementia missed its primary outcome of change in cerebral glucose metabolic rate, yet scores on the ADAS-Exec composite declined more slowly in treated patients, suggesting the drug was safe and possibly active. A real-world target-trial emulation study found that patients with T2DM treated with semaglutide had a 67% lower risk of a first AD diagnosis over three years compared with insulin treatment. In Parkinson’s disease, exenatide-treated patients showed a five-point advantage on the Mattis Dementia Rating Scale-2 that persisted after drug withdrawal, and a recent meta-analysis of five randomized trials confirmed improvements in both motor and nonmotor symptoms. A large TriNetX cohort study reported that semaglutide or tirzepatide use was associated with significantly reduced dementia (HR 0.63) and ischemic stroke (HR 0.81) compared with other antidiabetic drugs.

Then came the disappointments. The phase III EVOKE and EVOKE Plus trials—which enrolled 1,855 and 1,953 participants respectively across 566 sites in 40 countries to test semaglutide in early-stage symptomatic AD—failed to confirm superiority over placebo in slowing disease progression as measured by the Clinical Dementia Rating–Sum of Boxes score. Mean changes in CDR-SB from baseline to week 104 were nearly identical between semaglutide and placebo groups. Encouragingly, semaglutide did improve AD-related biomarkers, including canonical CSF markers such as p-tau181 and p-tau217 and neuroinflammatory markers such as YKL-40, with changes in the 5–10% range—but these biomarker shifts did not translate into delayed cognitive decline. On the SGLT2i front, however, large cohort data remain favorable: in a study of more than 708,000 patients with T2D, SGLT2i use was associated with substantially lower incidence of overall dementia (2.9% versus 6.7%; adjusted HR 0.77) compared with DPP4 inhibitors, across vascular dementia, AD, and other subtypes, alongside markedly lower all-cause mortality. A separate phase II trial found that empagliflozin lowered CSF tau and modulated immune and inflammatory biomarkers in patients with amnestic MCI or AD without diabetes, and a single-arm study detected reduced brain glutamate and upregulated IGF-1 and insulin signaling proteins in neuronal-origin extracellular vesicles after just 14 days of treatment.

The authors argue that the field’s next steps are clear: rigorously designed randomized controlled trials specifically enrolling patients with AD or other neurodegenerative diagnoses, standardized neurocognitive batteries, molecular and imaging biomarkers, and extended follow-up periods. Promising candidate biomarkers—plasma neurofilament light chain, GFAP, and the p-tau/β-amyloid ratio—could help identify which patients stand to benefit most, but require longitudinal validation in diabetic populations. Combination strategies also merit attention; preliminary evidence suggests that dapagliflozin paired with cognitive behavior training improved cognitive function and quality of life in elderly patients with T2D and MCI, outperforming pharmacological treatment alone. The therapeutic landscape may broaden further still: dual GIP/GLP-1 receptor agonists such as tirzepatide may modulate central insulin signaling, mitochondrial bioenergetics, and synaptic plasticity in ways that selective GLP-1 agonism alone cannot, opening a next-generation chapter in metabolic neuroprotection.

For now, the message to clinicians and the millions of patients living with type 2 diabetes is one of measured hope. The convergence of epidemiology, molecular biology, animal data, and large observational cohorts makes a persuasive case that glucose-lowering drugs could become genuine tools against dementia—and the pharmaceutical industry’s willingness to run massive phase III AD trials with diabetes drugs signals how seriously the hypothesis is now taken. But as the EVOKE results demonstrated, improved biomarkers do not guarantee slowed decline, and heterogeneity among study populations, treatment durations, and outcome measures continues to frustrate definitive conclusions. Whether incretin-based therapies, SGLT2 inhibitors, and DPP4 inhibitors can ultimately earn a place in dementia prevention will depend on the biomarker-driven, well-controlled trials now underway—trials that will determine if protecting the brain’s metabolism is truly the next frontier of neurology.

Diabetic peripheral neuropathy, the progressive damage to peripheral nerves caused by chronic high blood sugar, affects roughly half of people with diabetes over their lifetime and sets the stage for a cascade of devastating outcomes. When sensation in the feet is lost, minor injuries go unnoticed, wounds fail to heal, ulcers develop, and infections can burrow into bone. In the worst cases, the resulting osteomyelitis or the fragmented, inflamed joints of Charcot neuroarthropathy end in amputation. The condition is also a marker of systemic vulnerability; patients with neuropathic foot complications face substantially elevated mortality. With GLP-1 receptor agonists now prescribed to millions of people worldwide, understanding how these drugs influence the neuropathic foot has become a pressing clinical question.

Led by Fady Tawfik of Howard University College of Medicine, with colleagues at Texas A&M University College of Medicine and the University of Maryland School of Medicine, the research team turned to the TriNetX US Collaborative Network, a federated database aggregating de-identified electronic health records from dozens of American healthcare organizations. They identified adults with a diagnosis of type 2 diabetes mellitus and diabetic neuropathy, unspecified, coded under ICD-10-CM as E11.40, who had newly initiated either a GLP-1 receptor agonist or a DPP-4 inhibitor. Both drug classes act on the incretin system—the hormonal axis that amplifies insulin secretion after meals—but through different mechanisms. GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone directly and resist enzymatic breakdown, while DPP-4 inhibitors block the enzyme dipeptidyl peptidase-4 that normally degrades endogenous GLP-1, modestly prolonging its action.

Because patients prescribed these drugs often differ systematically in age, weight, kidney function, and overall disease burden, naive comparisons would be misleading. The investigators therefore applied 1:1 propensity score matching, a statistical technique that pairs each GLP-1 receptor agonist user with a DPP-4 inhibitor user who shares a similar demographic and clinical profile, including comorbidities and concomitant medications. After exclusions and matching, the final cohorts contained 19,770 patients per group, well balanced on the measured baseline covariates. The researchers then tracked five outcomes over one and two years: diabetic foot ulcer, lower-extremity amputation, osteomyelitis of the foot or ankle, Charcot neuroarthropathy, and all-cause mortality. Time-to-event analyses employed Kaplan–Meier curves and Cox proportional hazards models, with a Bonferroni correction setting the threshold for statistical significance at p less than 0.01 to guard against false positives across multiple comparisons.

The headline result concerned foot ulcers, the most common entry point into the cycle of neuropathic foot disease. At one year, 2.2 percent of GLP-1 receptor agonist users had been diagnosed with a diabetic foot ulcer compared with 2.7 percent of DPP-4 inhibitor users, corresponding to a hazard ratio of 0.813 with a 95 percent confidence interval of 0.716 to 0.922. In practical terms, the GLP-1 group experienced roughly a 19 percent relative reduction in ulcer risk over the first year. All-cause mortality was also lower in the GLP-1 group, a finding the authors interpreted as hypothesis-generating rather than definitive, given the observational design and the possibility of residual confounding.

Not every result favored the newer drugs. The apparent survival advantage and ulcer reduction came alongside an unexpected signal: Charcot neuroarthropathy occurred in 0.3 percent of GLP-1 users versus 0.2 percent of DPP-4 inhibitor users, a hazard ratio of 1.993 with a confidence interval of 1.297 to 3.064, meaning nearly a doubling of risk that reached statistical significance. By contrast, rates of lower-extremity amputation, at 0.5 percent in both groups, and foot or ankle osteomyelitis, at 0.4 percent in both groups, were indistinguishable, with hazard ratios crossing unity comfortably.

Why might a drug that reduces foot ulcers simultaneously raise the risk of Charcot neuroarthropathy? The authors and prior literature point to several plausible mechanisms. Charcot neuroarthropathy is widely understood as an “imperfect storm”: an injury to an insensate foot triggers an exaggerated inflammatory response in which osteoclast-driven bone resorption outpaces repair, producing fractures, joint disorganization, and the classic rocker-bottom deformity. Rapid improvements in glycemic control are a recognized trigger for acute neuropathic and Charcot events, a phenomenon related to treatment-induced neuropathy of diabetes, in which abruptly normalized blood sugar provokes acute painful neuropathy and arterio-venous shunting in nerve and bone microvasculature. GLP-1 receptor agonists are potent glucose-lowering agents, and their initiation in patients with poorly controlled diabetes could reproduce this dynamic, destabilizing bone in a foot already numbed by neuropathy.

Counteracting mechanisms may explain the ulcer benefit. Experimental work has shown that GLP-1 receptor signaling exerts neuroprotective and anti-inflammatory effects on peripheral nerves. Studies in diabetic rodent models demonstrated that the GLP-1 receptor agonist exendin-4 improved experimental polyneuropathy, and research in streptozotocin-induced diabetic rats found that GLP-1 receptor activation ameliorated nerve dysfunction by damping the p38 MAPK and nuclear factor kappa-B inflammatory pathways. Human imaging studies have reported that GLP-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy, and a recent meta-analysis in the Journal of Neurochemistry concluded that the class shows favorable effects on diabetic peripheral neuropathy overall. Independent of nerves, GLP-1 signaling appears to accelerate wound repair: liraglutide facilitated keratinocyte migration and healing through the PI3K/Akt pathway, exendin-4 accelerated diabetic wound closure in surgical models, and recent reviews describe GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic wounds, partly through vascular endothelial growth factor signaling. Fewer ulcers and better healing would naturally translate into fewer deep infections, which is consistent with the similar osteomyelitis rates despite different ulcer trajectories.

The findings land in a contentious literature. Previous emulated target trials have produced divergent results: one published in Diabetes Care comparing GLP-1 receptor agonists with SGLT2 inhibitors found differential amputation outcomes between classes, while another in Annals of Internal Medicine examined sodium-glucose cotransporter-2 inhibitors against GLP-1 receptor agonists for diabetic foot disease with mixed conclusions. A pharmacological database study in Diabetes, Obesity and Metabolism examined incretin-based therapy and foot ulcer risk broadly, and a nationwide observational study in Diabetes Care reported that GLP-1 receptor agonists were associated with reduced mortality after diabetic foot ulcers. The new Journal of Neurology analysis is among the first to focus specifically on patients who already have neuropathy—the population at highest risk—and the first in this context to surface Charcot neuroarthropathy as a comparative safety signal between incretin classes.

The authors are careful about causality. As a retrospective cohort study of administrative coding data, the analysis cannot prove that GLP-1 receptor agonists caused fewer ulcers or more Charcot feet. Unmeasured confounding remains possible despite propensity matching; physicians may preferentially prescribe GLP-1 receptor agonists to patients deemed healthier or more adherent, a phenomenon known as channeling bias that has been documented in glucose-lowering drug studies. Coding of Charcot neuroarthropathy is uncommon and inconsistently applied, and although the doubling of risk reached the corrected significance threshold, the absolute numbers were small—roughly three additional cases per thousand patients per year. The modest absolute reduction in ulcers, about five additional ulcer-free patients per thousand at one year, likewise requires context.

Even so, the study carries practical messages. For the growing population of patients with type 2 diabetes and established neuropathy, GLP-1 receptor agonist therapy appears, on balance, favorable for foot health, reinforcing their established cardiovascular and mortality benefits rather than undermining them. But clinicians initiating these potent glucose-lowering agents in patients with preexisting nerve damage should remain alert to the rare possibility of rapid glycemic improvement triggering neuropathic worsening or Charcot joint destruction. The authors emphasize that vigilant foot surveillance during therapy, including prompt evaluation of warmth, swelling, or deformity in an insensate foot, is warranted. Charcot neuroarthropathy caught early can be treated with offloading and immobilization before irreversible deformity sets in; caught late, it is a leading cause of amputation. As GLP-1 receptor agonists continue their meteoric rise from injectable diabetes drugs to near-universal metabolic therapy, this study is a reminder that even celebrated drugs demand close study of their effects on the body’s most vulnerable territories—and that the diabetic foot, more than most, keeps score.

The rapid rise of glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, is transforming the treatment of obesity—and exposing a problem that medicine has struggled to solve for decades. These drugs can reduce appetite, alter food-reward pathways and improve several cardiometabolic measures, including blood-glucose control and cardiovascular risk factors. Their popularity has surged across clinical practice, private health services and, increasingly, self-directed online markets. But a new commentary in BMC Medicine argues that the medication revolution will not deliver its full promise unless it is paired with sustained psychological, behavioral and social support. Brunna Boaventura of the Federal University of Santa Catarina in Brazil and Stuart W. Flint of the University of Leeds in the UK warn that prescribing medication without helping people build durable behavior-change skills could create a modern version of an old mistake: treating body weight as an isolated problem rather than as one part of a complex chronic disease.

The authors’ central message is not that lifestyle interventions should replace medication. Instead, they argue that obesity care must become genuinely multimodal, combining pharmacological treatment with structured behavioral support and, when appropriate, psychological, nutritional, medical and surgical care. The World Health Organization recognizes obesity as a chronic, relapsing disease, meaning that long-term management is often necessary even after substantial weight loss. Yet in routine healthcare, behavioral treatment is frequently reduced to brief advice—“eat better,” “exercise more” or “monitor your weight”—rather than delivered as a continuous clinical service. That implementation gap has several causes: many clinicians receive limited training in behavior-change techniques, referral routes to dietitians, psychologists and health coaches may be weak, reimbursement is often inadequate, and healthcare systems rarely account for the social and structural conditions that shape daily choices. The result is a mismatch between the biological complexity of obesity and the simplicity of the support many patients receive.

GLP-1 RAs make that mismatch more consequential because their benefits are closely tied to continued treatment and individual response. The drugs mimic or enhance signaling by hormones involved in appetite regulation and glucose metabolism. By activating GLP-1 receptors, they can slow gastric emptying, increase feelings of fullness and reduce food intake; their metabolic effects can also improve glycemic control. But these physiological changes do not automatically resolve the habits, routines, emotional triggers, social pressures or practical barriers that influence eating and physical activity. Nor do they guarantee identical outcomes for every patient. Some people respond strongly, others less so, and side effects, cost or limited availability can lead to treatment interruption. A systematic review and meta-analysis cited by Boaventura and Flint examined 37 studies involving 9,341 participants and found that weight regain after stopping obesity medication occurred faster than regain following behavioral weight-management programs, regardless of the amount of weight initially lost. The finding does not mean medication is ineffective; it shows why medication should be embedded in a plan designed for continuity and adaptation.

Behavior change is not a matter of receiving information and then demonstrating sufficient willpower. It emerges from the interaction of cognitive processes, emotions, motivation, self-regulation and the environment in which a person lives. An individual may intend to change eating patterns but face irregular work schedules, food insecurity, chronic stress, limited access to safe exercise spaces or a history of negative experiences in healthcare. Motivation itself can fluctuate, while habits are often triggered by cues that operate outside conscious awareness. Effective support therefore involves more than education. It can include collaborative goal setting, monitoring progress, identifying barriers, developing coping strategies, reinforcing self-efficacy and adjusting plans as circumstances change. Such interventions are most effective when they are person-centered: goals should reflect health, functioning and quality of life, not only the number on a scale. The authors say this broader approach is essential as drug-centered models become more common, because a prescription can influence appetite without supplying the skills and support needed to sustain health-related behaviors over years.

The commentary places weight stigma at the center of this challenge. People living with obesity frequently encounter moral judgment in clinics, workplaces, media and everyday life, where body size is often interpreted as evidence of laziness, irresponsibility or poor character. Those experiences can produce internalized weight stigma—the adoption of negative cultural beliefs about one’s own body—which is associated with distress, reduced self-confidence and disengagement from care. A clinical encounter that focuses narrowly on weight loss may unintentionally intensify the problem, particularly when treatment success is defined by a predetermined percentage of weight reduction. By contrast, addressing stigma and its consequences can improve eating self-efficacy, quality of life, treatment acceptability and patients’ ability to cope with difficult experiences. The authors argue that behavior-change support should therefore help people manage not only diet and physical activity, but also shame, discrimination, body-image concerns, fears of regain and the psychological burden of being judged.

The arrival of GLP-1 medications has produced a complicated cultural shift. On one hand, the drugs may challenge the idea that obesity is simply a failure of self-control by highlighting the roles of appetite, satiety, food reward and biological regulation. On the other hand, people who use them may still be criticized for taking what some regard as a shortcut. Research cited in the commentary suggests that GLP-1 use can influence how women with different body weights are evaluated, but the authors caution against assuming that medication automatically removes stigma. A person may lose weight and still carry years of negative self-beliefs, altered body image or anxiety about returning to a previous size. Physical change can itself require psychological adjustment, especially when identity, relationships and social treatment have been shaped by body weight. These consequences may persist even when a medication is working medically. In that sense, successful obesity care must address the lived experience of treatment rather than treating weight reduction as the sole endpoint.

Existing behavioral programs may not be broad enough for this new era. The intensive behavioral therapy model covered by the US Centers for Medicare & Medicaid Services emphasizes diet, physical activity and self-monitoring, with delivery largely centered on physicians and nurses and success commonly tied to weight-loss thresholds. Those components can be useful, but Boaventura and Flint argue that a weight-centered framework overlooks outcomes that matter to patients and health systems, including cardiometabolic health, mobility, mental well-being, quality of life and quality-adjusted life years. It may also fail to include professionals with specialized expertise in counseling, psychology, nutrition and sustained coaching. A broader model would measure whether people can maintain beneficial routines, manage distress, participate more fully in daily life and reduce health risks—even when weight loss is modest or fluctuates. This distinction is scientifically important because body weight is only one observable outcome of a treatment, while metabolic health and psychological functioning may change along different trajectories.

The risks become sharper when access to regulated care is limited. Demand, cost and shortages have encouraged some people to seek GLP-1 RAs through online sellers, private services or self-directed pathways. Such routes can separate medication access from clinical assessment, dose monitoring, side-effect management and follow-up. They may also expose patients to counterfeit or falsified products, inappropriate prescribing and fragmented care. When obtaining the drug becomes the primary objective, behavioral and psychosocial support can be treated as optional extras rather than essential parts of treatment. The authors do not suggest that every patient must receive an identical package of services, but they insist that safe care requires more than dispensing a medication. Patients need reliable information, supervision and access to appropriately trained professionals who can help them respond to changing appetite, adverse effects, treatment interruptions and the possibility of weight regain. Regulation, they argue, should focus not only on the products themselves but also on whether the surrounding service provides comprehensive care.

The policy implications extend beyond individual consultations. Multidisciplinary obesity treatment is widely recommended, yet it remains difficult to obtain in both public and private systems. Public-health programs need investment so that integrated services are available beyond specialist centers, while private care must confront the financial barriers created when several professionals and an expensive medication are combined. Health systems and regulators should ensure that obesity services include behavioral, psychological and social support, rather than allowing pharmacotherapy to become a substitute for chronic-care infrastructure. The authors describe this as an opportunity to redesign obesity treatment around empowerment and long-term health. GLP-1 RAs may be powerful tools, but they cannot by themselves teach people how to navigate stigma, stress, disrupted routines or the emotional consequences of bodily change. The future of obesity medicine, the commentary concludes, will be determined not simply by how many people receive these drugs, but by whether healthcare can surround them with the sustained, person-centered support required to make improvement safer and more durable.